Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML

Anna Wojtuszkiewicz, MSc, Yehuda G Assaraf, PhD, Gerrit Jansen, PhD, Kazunori Koide, PhD, Robert K. Bressin, Upamanyu Basu, Edwin Sonneveld, PhD, Elisa Giovannetti, PhD, Gertjan Kaspers, MD PhD, Jacqueline Cloos, PhD

Blood (2014) 124 (21): 924.

https://doi.org/10.1182/blood.V124.21.924.924

Published: 2014

Journal Articles

Genetic Aberrations As Putative MRD Targets in Childhood Acute Myeloid Leukaemia

Edwin Sonneveld, PhD, Valerie De Haas, Gertjan Kaspers, MD PhD, C. Michel Zwaan, Eveline Bont, MD PhD, Vincent van der Velden, PhD

Blood (2014) 124 (21): 2331.

https://doi.org/10.1182/blood.V124.21.2331.2331

Published: 2014

Journal Articles

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

Gertjan Kaspers, MD PhD, Denise Niewerth, MSc, Satianand Ramnarain, MSc, Andishe Attarbaschi, MD, André Baruchel, MD, Evelina S De Bont, MDPhD, Franca Fagioli, MD, Barbara De Moerloose, MD PhD, Karsten Nysom, MD, Giuseppe Palumbo, MD, Dirk Reinhardt, MD PhD, Pierre-Simon Rohrlich, MDPhD, Pauline Simon, MD, Arend von Stackelberg, MD, C. Michel Zwaan, MD PhD

Blood (2014) 124 (21): 2290.

https://doi.org/10.1182/blood.V124.21.2290.2290

Published: 2014

Journal Articles

Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML

Blood (2014) 124 (21): 481.

https://doi.org/10.1182/blood.V124.21.481.481

Published: 2014

Journal Articles

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

Denise Niewerth, MSc, Johan van Meerloo, MSc, Yehuda Assaraf, PhD, Gerrit Jansen, PhD, Tessa C Hendrickx, BSc, Christopher J. Kirk, Ph.D, Janet Anderl, MS, Sonja Zweegman, MD PhD, Jacqueline Cloos, PhD, Gertjan Kaspers, MD, PhD

Blood (2013) 122 (21): 3841.

https://doi.org/10.1182/blood.V122.21.3841.3841

Published: 2013

Journal Articles

A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia

Wing H. Tong, MD, Rob Pieters, Gertjan Kaspers, MD, PhD, Maroeska D.W.M. te Loo, MD, PhD, Marc Bierings, Cor van den Bos, MD, PhD, Wouter J.W. Kollen, MD, PhD, Wim C.J. Hop, PhD, Joachim Boos, MD, PhD, Mary V. Relling, PharmD, Hans Juergen Kuehnel, MD, Wim J Tissing, MD, PhD, Inge M. van der Sluis, MD, PhD

Blood (2013) 122 (21): 2634.

https://doi.org/10.1182/blood.V122.21.2634.2634

Published: 2013

Journal Articles

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Gertjan Kaspers, MD, PhD, Ron Mathot, PharmD PhD, Satianand Ramnarain, MSc, Denise Niewerth, MSc, Franco Locatelli, MD, PhD, Eveline S.J.M De Bont, MD, PhD, Franca Fagioli, MD, Pierre Rohrlich, MD, Arend von Stackelberg, Michel Zwaan

Blood (2013) 122 (21): 1439.

https://doi.org/10.1182/blood.V122.21.1439.1439

Published: 2013

Journal Articles

High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia

Katarina Reinhardt, PhD, C. Michel Zwaan, MD, PhD, Michael Dworzak, Jasmijn D.E. de Rooij, MD, Gertjan Kaspers, MD, PhD, Thomas Lehrnbecher, Henrik Hasle, Toralf Bernig, Jean-Michel Cavuela, Alexandra Kolenova, MD, PhD, Jochen Harbott, Jean-Pierre Bourquin, MD, PhD, Jan Stary, Ursula Creutzig, Dirk Reinhardt, MD

Blood (2012) 120 (21): 888.

https://doi.org/10.1182/blood.V120.21.888.888

Published: 2012

Journal Articles

Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic Leukemia with Pegasparaginase and Erwinia Asparaginase: The Impact of Expensive Chemotherapy

Wing H. Tong, MD, Inge M. van der Sluis, MD, PhD, Cathelijne Alleman, MSc, Raphaele RL van Litsenburg, MD, PhD, Gertjan Kaspers, MD, PhD, Rob Pieters, MD, PhD, Carin A. Uyl-de Groot, PhD

Blood (2012) 120 (21): 4227.

https://doi.org/10.1182/blood.V120.21.4227.4227

Published: 2012

Journal Articles

Clinical Impact of Additional Cytogenetic Aberrations and Treatment in Pediatric t(8;21)-Positive AML: Results from an International Retrospective I-BFM-SG Study

Blood (2012) 120 (21): 884.

https://doi.org/10.1182/blood.V120.21.884.884

Published: 2012

Journal Articles

Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection.

Costa Bachas, MSc, Gerrit-Jan Schuurhuis, Iris H.I.M. Hollink, MD, Bianca F. Goemans, MD, PhD, Dirk Reinhardt, MD, PhD, Christian M Zwaan, MD, PhD, Marry M. van den Heuvel, MD, PhD, Eveline S.J.M de Bont, Elisabeth R. Van Wering, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2009) 114 (22): 1624.

https://doi.org/10.1182/blood.V114.22.1624.1624

Published: 2009

Journal Articles

The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.

Niels E Franke, MD, MSc, Johan van Meerloo, B.ASc, Linda Slot, MSc, Xiaoming Li, PhD, Tabitha E Wood, PhD, Katarina Vojtekova, MSc, Sue Ellen Verbrugge, MSc, Gertjan Kaspers, MD, PhD, Robert A. Batey, PhD, Aaron D. Schimmer, MD, PhD, Gerrit Jansen, PhD, Jacqueline Cloos, PhD

Blood (2009) 114 (22): 940.

https://doi.org/10.1182/blood.V114.22.940.940

Published: 2009

Journal Articles

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.

Hendrik JM de Jonge, Peter Valk, PhD, Kim R Kampen, Arja ter Elst, PhD, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD, C. Michel Zwaan, MD, PhD, Marry M van den Heuvel-Eibrink, MD, PhD, Willem A. Kamps, MD, PhD, Ruud Delwel, PhD, Bob Lowenberg, MD, PhD, Eveline S de Bont, MD, PhD

Blood (2009) 114 (22): 997.

https://doi.org/10.1182/blood.V114.22.997.997

Published: 2009

Journal Articles

High Frequency of Copy Number Variations in Myeloid Leukemia of Down Syndrome.

Marjolein Blink, MD, Marry M van den Heuvel-Eibrink, MD, PhD, Brian Balgobind, MD, Iris H.I.M. Hollink, MD, Valerie de Haas, MD, PhD, Gertjan Kaspers, MD, PhD, Dirk Reinhardt, MD, PhD, Henrik Hasle, MD, PhD, C. Michel Zwaan, MD, PhD

Blood (2009) 114 (22): 3242.

https://doi.org/10.1182/blood.V114.22.3242.3242

Published: 2009

Journal Articles

Identification of Gene Expression Signatures Accurately Predicting Cytogenetic Subtypes in Pediatric Acute Myeloid Leukemia.

Brian V Balgobind, MD, Marry M van den Heuvel-Eibrink, MD, PhD, Renee X Menezes, Dirk Reinhardt, MD, PhD, Iris H.I.M. Hollink, MD, Susan T.J.C.M. Arentsen-Peters, Elisabeth R van Wering, Gertjan Kaspers, MD, PhD, Jaqueline Cloos, PhD, Eveline S.J.M de Bont, Andre Baruchel, MD, Jean-Michel Cayuela, PhD, Jan Stary, MD, PhD, Jan Trka, MD., PhD, Berna Beverloo, PhD, Rob Pieters, Christian M Zwaan, MD, PhD, Monique L. Den Boer, MSc, PhD

Blood (2008) 112 (11): 1509.

https://doi.org/10.1182/blood.V112.11.1509.1509

Published: 2008

Journal Articles

EVI1 Overexpression in Pediatric Acute Myeloid Leukemia Associated with Unfavorable Subtypes.

Brian V Balgobind, MD, Sanne Lugthart, MD, Iris H.I.M. Hollink, MD, Susan T.J.C.M. Arentsen-Peters, Elisabeth R van Wering, Sibold S.N. de Graaf, MD, PhD, Dirk Reinhardt, MD, PhD, Gertjan Kaspers, MD, PhD, Jan Stary, MD, PhD, Jan Trka, MD, PhD, Martin Zimmermann, PhD, Ruud Delwel, PhD, Rob Pieters, Christian M Zwaan, MD, PhD, Marry M van den Heuvel-Eibrink, MD, PhD

Blood (2008) 112 (11): 1802.

https://doi.org/10.1182/blood.V112.11.1802.1802

Published: 2008

Journal Articles

Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse

Costa Bachas, MSc, Gerrit J. Schuurhuis, PhD, Lê D Huynh, BSc, Bianca F. Goemans, MD, PhD, D. Reinhardt, MD, PhD, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD

Blood (2008) 112 (11): 2540.

https://doi.org/10.1182/blood.V112.11.2540.2540

Published: 2008

Journal Articles

Liposomal Daunorubicin Causes Only Low Cardiotoxicity in Pediatric AML Patients.

Ursula Creutzig, MD, Martin Zimmermann, Gertjan Kaspers, MD, PhD, Dirk Reinhardt, MD, PhD

Blood (2008) 112 (11): 1940.

https://doi.org/10.1182/blood.V112.11.1940.1940

Published: 2008

Journal Articles

Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.

Annette Sander, MD, Martin Zimmermann, PhD, Dirk Reinhardt, MD, PhD, Michael Dworzak, MD, PhD, Gertjan Kaspers, MD, PhD, Ursula Creutzig, MD, PhD

Blood (2008) 112 (11): 963.

https://doi.org/10.1182/blood.V112.11.963.963

Published: 2008

NARROW

Spliceosome Inhibitor Meayamycin B As a Novel Potential Chemotherapeutic Agent in ALL and AML

Genetic Aberrations As Putative MRD Targets in Childhood Acute Myeloid Leukaemia

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML

The Novel Immunoproteasome Inhibitor PR-924: Anti-Leukemic Activity and Mechanisms Of Resistance

A Prospective Study On Drug Monitoring Of Pegasparaginase and Erwinia Asparaginase and Asparaginase Antibodies In Pediatric Acute Lymphoblastic Leukemia

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia

Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic Leukemia with Pegasparaginase and Erwinia Asparaginase: The Impact of Expensive Chemotherapy

Clinical Impact of Additional Cytogenetic Aberrations and Treatment in Pediatric t(8;21)-Positive AML: Results from an International Retrospective I-BFM-SG Study

Frequent Instability of Type I and II Aberrations Between Diagnosis and Relapse Observed in Pediatric Aml; Implications for Targeted Therapy and MRD Detection.

The Novel Proteasome Inhibitor 5-Amino-8-Hydroxyquinole (5AHQ) Overcomes Bortezomib Resistance in Malignant Hematological Cell Line Models Harboring Mutations in the PSMB5 Gene.

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.

High Frequency of Copy Number Variations in Myeloid Leukemia of Down Syndrome.

Identification of Gene Expression Signatures Accurately Predicting Cytogenetic Subtypes in Pediatric Acute Myeloid Leukemia.

EVI1 Overexpression in Pediatric Acute Myeloid Leukemia Associated with Unfavorable Subtypes.

Changes in Type I Mutations Between Initial and Relapse Samples of Pediatric AML Patients Occur Frequently and Are Associated with Time to Relapse

Liposomal Daunorubicin Causes Only Low Cardiotoxicity in Pediatric AML Patients.

Improvement of Survival after Relapse in Pediatric AML Over the Last Two Decades Is Related to a Standardized, Consistent and Intensive Relapse Treatment.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only